L
Leszek Bidzan
Researcher at Gdańsk Medical University
Publications - 62
Citations - 645
Leszek Bidzan is an academic researcher from Gdańsk Medical University. The author has contributed to research in topics: Dementia & Population. The author has an hindex of 13, co-authored 56 publications receiving 491 citations.
Papers
More filters
Journal ArticleDOI
A Polish and German Population Study of Quality of Life, Well-Being, and Life Satisfaction in Older Adults During the COVID-19 Pandemic.
Ilona Bidzan-Bluma,Monika Bidzan,Paweł Jurek,Leszek Bidzan,Jessica Knietzsch,Marcus Stueck,Mariola Bidzan +6 more
TL;DR: Quality of life, life satisfaction, and well-being during the pandemic is affected by age, trait anxiety, and Coronavirus threat.
Journal ArticleDOI
Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
TL;DR: Vortioxetine was safe and effective in treating adults with GAD in this multinational population, and active treatment resulted in a significantly higher rate of remission.
Journal ArticleDOI
Aggressive and impulsive behavior in Alzheimer’s disease and progression of dementia
TL;DR: There is a relationship between cognitive functioning disorders and the intensification of aggressive and impulsive behaviours as the disease progresses.
Journal ArticleDOI
Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.
Karla Alaka,William Noble,Angel L. Montejo,Héctor Dueñas,Autar Munshi,Jeffrey R. Strawn,Alan Lenox-Smith,Jonna Ahl,Leszek Bidzan,Brita Dorn,Susan Ball,Susan Ball +11 more
TL;DR: This was a flexible‐dosed study to evaluate the efficacy and safety of duloxetine 30–120 mg once daily in the treatment of generalized anxiety disorder (GAD) in older adult patients.
Journal ArticleDOI
Beta-Amyloid Peptides Enhance the Proliferative Response of Activated CD4+CD28+ Lymphocytes from Alzheimer Disease Patients and from Healthy Elderly
TL;DR: It is suggested that the effect of Aβ peptides on the immune system of AD patients does not depend on the specific reactivity to Aβ epitope(s), but is rather a consequence of an unspecific modulation of the cell cycle dynamics and cytokine production by T cells, occurring simultaneously in a huge proportion of A β peptide-exposed T lymphocytes and affecting theimmune system performance.